← Back to Clinical Trials
Recruiting NCT07213648

NCT07213648 Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07213648
Status Recruiting
Phase
Sponsor University of Virginia
Condition Huntington Disease
Study Type INTERVENTIONAL
Enrollment 136 participants
Start Date 2025-11-20
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
MindTrails-MovementWaitlist Control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 136 participants in total. It began in 2025-11-20 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess preliminary efficacy of a tailored cognitive bias modification for interpretation (CBM-I) app for reducing anxiety in Huntington's disease and Parkinson's disease.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnosis of Huntington's disease or Parkinson's disease (genetic diagnosis of HD also acceptable) * With anxiety symptoms (NeuroQoL Anxiety ≥12) Exclusion Criteria: * Cognitive decline precluding ability to consent or complete the intervention (MoCA 5 min/telephone ≤11) * Unable to read and understand English * Does not have regular access to an internet-connected device, capable of downloading and installing the mobile application (i.e., tablet or iPhone running iOS 10 or later or an Android phone running Android 5.0 or later) * Not located in the USA * \<21 years old * Active suicidality based on the answer "yes" to questions 4, 5, or 6b of the Columbia-Suicide Severity Rating Scale (Screen version)

Contact & Investigator

Central Contact

Jessie Gibson, PhD, RN

✉ MindTrailsMovement@uvahealth.org

📞 434-924-0107

Frequently Asked Questions

Who can join the NCT07213648 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07213648 currently recruiting?

Yes, NCT07213648 is actively recruiting participants. Contact the research team at MindTrailsMovement@uvahealth.org for enrollment information.

Where is the NCT07213648 trial being conducted?

This trial is being conducted at Charlottesville, United States.

Who is sponsoring the NCT07213648 clinical trial?

NCT07213648 is sponsored by University of Virginia. The trial plans to enroll 136 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology